Shuangtianshi Creature
Latest round
- Angel
Last raised
- Apr 2021
Total raised
- Undisclosed
Investors
- 2
About Shuangtianshi Creature
Established in 2021 and based in Nanchang, China, Shuangtianshi Creature is a developer of antitumor drugs., Ltd. The founder, Zixia Feng, has PhD in Medicinal Chemistry and was CSO of Novartis. The company focuses on the research and development of targeted anti-tumor small molecule drugs. Pharmacodynamic test shows that the drug has inhibitory effect on lung cancer, gastric cancer, ovarian cancer and other tumors.
Who invested in Shuangtianshi Creature
2 investors across 1 round
See all investors in Shuangtianshi Creature
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Angel
Apr 9, 2021
Amount
Undisclosed
Investors
Questions about Shuangtianshi Creature
Who invested in Shuangtianshi Creature?
Shuangtianshi Creature has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Shuangtianshi Creature raised?
Shuangtianshi Creature has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Shuangtianshi Creature last raise money?
Shuangtianshi Creature's most recent round on record is a Angel, in Apr 2021.
What does Shuangtianshi Creature do?
Established in 2021 and based in Nanchang, China, Shuangtianshi Creature is a developer of antitumor drugs.
Where is Shuangtianshi Creature headquartered?
Shuangtianshi Creature is headquartered in Nanchang, China.
Which VCs invest in companies like Shuangtianshi Creature?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back pharmaceuticals companies at Shuangtianshi Creature's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Angel
Raising like Shuangtianshi Creature? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.